Akebia Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Akebia reported Q2 2026 Vafseo net product revenues of $21.3M (34% QoQ growth) with 10,500+ patients on therapy and ~1,200 prescribers. The VOICE interim analysis (n=2,116) met stopping criteria, showing statistically significant improved safety: win odds 1.16 (95% CI 1.06–1.28, p=0.0016) for all-cause mortality and hospitalization vs erythropoiesis stimulating agents, driven by hospitalization reduction. Akebia initiated Phase 2 basket trial of ebribafusp for IgA nephropathy, lupus nephritis, and C3 glomerulopathy (up to 30 patients, initial data 2027); net loss Q2 $8.9M vs net income $0.2M Q2 2025; cash position $155.5M.
Why this rating
Vafseo ramp ($21.3M annualized ~$85M) is meaningful vs $946M market cap (~9%). VOICE safety data validates competitive positioning vs ESA; phase 2 pipeline expansion is moderate progress. Q2 loss and Auryxia decline offset gains.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.